The study is a phase 3, multicenter, randomized, open-label, non-inferiority study that investigated switching to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy. Doravirine and islatravir were effective and well tolerated. They represent the first non-INSTI-based two-drug regimen for the treatment of HIV-1. In one part of the study, 513 adults were randomized 2:1 to DOR/ISL (n=342) or continuation of BIC/FTC/TAF (n=171). The primary efficacy endpoint was the percentage of participants with HIV-1 RNA ≥50 copies/mL at 48 weeks (non-inferiority margin of 4%). In another part, 551 adults were randomized 2:1 to DOR/ISL (n=366) or continuation of bART (n=185). At 48 weeks, 1.4% in the DOR/ISL group and 4.9% in the bART group had a viral load ≥50 copies/mL, demonstrating non-inferiority (difference -3.6%, 95% CI -7.8 to -0.8).[1] Safety and efficacy findings support the continued development of islatravir with the potential for long-term efficacy.[1]